• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胸腺基质淋巴细胞生成素在特应性皮炎发病机制中的作用。

The role of thymic stromal lymphopoietin in the immunopathogenesis of atopic dermatitis.

机构信息

Allergy/Immunology Division, Albert Einstein College of Medicine, Bronx, NY 10463, USA.

出版信息

Clin Exp Allergy. 2011 Nov;41(11):1515-20. doi: 10.1111/j.1365-2222.2011.03797.x. Epub 2011 Jun 14.

DOI:10.1111/j.1365-2222.2011.03797.x
PMID:21672057
Abstract

Atopic dermatitis (AD), a skin disease characterized by pruritus and chronic inflammation, results from a complex interplay between environmental and genetic factors. Thymic stromal lymphopoietin (TSLP), an IL-7-like cytokine, is believed to propagate AD lesions through T helper 2 (Th2) polarization. This paper describes the immunologic mechanisms involving TSLP in the generation of allergic disease. Specifically in AD, TSLP has been shown to be an inducer of myeloid dendritic cells, Th2 responses, mast cells, and natural killer T cells, thereby leading to cytokine secretion and the development of AD. We hope that further understanding of the TSLP pathway and its role in the pathogenesis of AD will lead to improved clinical management of AD in the future.

摘要

特应性皮炎(AD)是一种以瘙痒和慢性炎症为特征的皮肤病,是环境和遗传因素复杂相互作用的结果。胸腺基质淋巴细胞生成素(TSLP)是一种类似于白细胞介素-7 的细胞因子,被认为通过辅助性 T 细胞 2(Th2)极化来促进 AD 病变。本文描述了 TSLP 在过敏性疾病发生中的免疫机制。具体在 AD 中,TSLP 已被证明可诱导髓样树突状细胞、Th2 反应、肥大细胞和自然杀伤 T 细胞,从而导致细胞因子分泌和 AD 的发展。我们希望对 TSLP 途径及其在 AD 发病机制中的作用的进一步了解将导致未来 AD 的临床管理得到改善。

相似文献

1
The role of thymic stromal lymphopoietin in the immunopathogenesis of atopic dermatitis.胸腺基质淋巴细胞生成素在特应性皮炎发病机制中的作用。
Clin Exp Allergy. 2011 Nov;41(11):1515-20. doi: 10.1111/j.1365-2222.2011.03797.x. Epub 2011 Jun 14.
2
Thymic stromal lymphopoietin-induced interleukin-17A is involved in the development of IgE-mediated atopic dermatitis-like skin lesions in mice.胸腺基质淋巴细胞生成素诱导的白细胞介素-17A参与小鼠IgE介导的特应性皮炎样皮肤损伤的发展。
Immunology. 2015 Dec;146(4):568-81. doi: 10.1111/imm.12528. Epub 2015 Sep 24.
3
Thymic stromal lymphopoietin-activated invariant natural killer T cells trigger an innate allergic immune response in atopic dermatitis.胸腺基质淋巴细胞生成素激活的固有自然杀伤 T 细胞在特应性皮炎中引发先天过敏性免疫反应。
J Allergy Clin Immunol. 2010 Aug;126(2):290-9, 299.e1-4. doi: 10.1016/j.jaci.2010.05.024. Epub 2010 Jul 10.
4
Thymic stromal lymphopoietin regulates eosinophil migration via phosphorylation of l-plastin in atopic dermatitis.胸腺基质淋巴细胞生成素通过在特应性皮炎中使l-原肌球蛋白磷酸化来调节嗜酸性粒细胞迁移。
Exp Dermatol. 2016 Nov;25(11):880-886. doi: 10.1111/exd.13111.
5
Heat-shock pretreatment reduces expression and release of TSLP from keratinocytes under Th2 environment.热休克预处理可降低Th2环境下角质形成细胞中TSLP的表达和释放。
Pediatr Allergy Immunol. 2016 Feb;27(1):62-9. doi: 10.1111/pai.12482. Epub 2015 Sep 30.
6
Thymic stromal lymphopoietin:a potential therapeutic target for allergy and asthma.胸腺基质淋巴细胞生成素:过敏和哮喘的潜在治疗靶点。
Curr Allergy Asthma Rep. 2006 Sep;6(5):372-6. doi: 10.1007/s11882-996-0006-7.
7
Keratinocytes in atopic dermatitis express abundant ΔNp73 regulating thymic stromal lymphopoietin production via NF-κB.特应性皮炎角质形成细胞通过 NF-κB 表达丰富的 ΔNp73 调节胸腺基质淋巴细胞生成素的产生。
J Dermatol Sci. 2017 Nov;88(2):175-183. doi: 10.1016/j.jdermsci.2017.06.017. Epub 2017 Jun 22.
8
Antagonistic effect of the inflammasome on thymic stromal lymphopoietin expression in the skin.炎症小体对皮肤中胸腺基质淋巴细胞生成素表达的拮抗作用。
J Allergy Clin Immunol. 2013 Dec;132(6):1348-57. doi: 10.1016/j.jaci.2013.06.033. Epub 2013 Aug 13.
9
Use of Physcion to Improve Atopic Dermatitis-Like Skin Lesions through Blocking of Thymic Stromal Lymphopoietin.使用大黄素通过抑制胸腺基质淋巴细胞生成素来改善特应性皮炎样皮肤损伤。
Molecules. 2019 Apr 15;24(8):1484. doi: 10.3390/molecules24081484.
10
Th2 Modulation of Transient Receptor Potential Channels: An Unmet Therapeutic Intervention for Atopic Dermatitis.Th2 调节瞬时受体电位通道:特应性皮炎治疗的未满足需求。
Front Immunol. 2021 Jun 30;12:696784. doi: 10.3389/fimmu.2021.696784. eCollection 2021.

引用本文的文献

1
Role of LECT2 in exacerbating atopic dermatitis: insight from and models via NF-κB signaling pathway.LECT2 在加重特应性皮炎中的作用:通过 NF-κB 信号通路从 和 模型中获得的见解。
Front Immunol. 2024 Aug 14;15:1439367. doi: 10.3389/fimmu.2024.1439367. eCollection 2024.
2
The Roles of Innate Immune Cells in Atopic Dermatitis.先天性免疫细胞在特应性皮炎中的作用。
J Innate Immun. 2024;16(1):385-396. doi: 10.1159/000539534. Epub 2024 Jul 18.
3
Site-Specific Transient Receptor Potential Channel Mechanisms and Their Characteristics for Targeted Chronic Itch Treatment.
靶向慢性瘙痒治疗的特定部位瞬时受体电位通道机制及其特征。
Biomolecules. 2024 Jan 15;14(1):107. doi: 10.3390/biom14010107.
4
Targeting the Epithelium-Derived Innate Cytokines: From Bench to Bedside.靶向上皮来源的固有细胞因子:从实验台到临床应用
Immune Netw. 2022 Feb 22;22(1):e11. doi: 10.4110/in.2022.22.e11. eCollection 2022 Feb.
5
Peripheral Mechanisms of Itch.瘙痒的外周机制。
J Invest Dermatol. 2022 Jan;142(1):31-41. doi: 10.1016/j.jid.2021.10.024. Epub 2021 Nov 24.
6
Prevalence and Risk Factors Associated with the Occurrence of Autoimmune Diseases in Patients with Alopecia Areata.斑秃患者自身免疫性疾病发生的患病率及相关危险因素。
J Inflamm Res. 2021 Sep 22;14:4881-4891. doi: 10.2147/JIR.S331579. eCollection 2021.
7
Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis.新型靶向生物制剂治疗特应性皮炎。
BioDrugs. 2021 Jul;35(4):401-415. doi: 10.1007/s40259-021-00490-x. Epub 2021 Jul 2.
8
Mast Cells in the Skin: Defenders of Integrity or Offenders in Inflammation?皮肤中的肥大细胞:完整性的捍卫者还是炎症的肇事者?
Int J Mol Sci. 2021 Apr 27;22(9):4589. doi: 10.3390/ijms22094589.
9
New and Emerging Therapies for Pediatric Atopic Dermatitis.儿科特应性皮炎的新疗法和新兴疗法。
Paediatr Drugs. 2019 Aug;21(4):239-260. doi: 10.1007/s40272-019-00342-w.
10
Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches.了解特应性皮炎的免疫景观:生物制剂和新兴治疗方法的时代。
Exp Dermatol. 2019 Jul;28(7):756-768. doi: 10.1111/exd.13911. Epub 2019 Apr 15.